The downregulation and anti-carcinogenic effects of SELENBP1 are assessed in numerous cancers, including kidney/lung/thyroid/stomach/esophagus/liver/breast/prostate/colon/pancreatic/head and neck/skin/bladder/uterine/nerve and ovary cancer. The gene discussed is SELENBP1; the disease is ovarian cancer.